...
首页> 外文期刊>Radiation oncology >The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly
【24h】

The value of primary and adjuvant radiotherapy for cutaneous squamous cell carcinomas of the head-and-neck region in the elderly

机译:老年人颈部地区皮肤鳞状细胞癌的主要和辅助放射疗法的价值

获取原文
   

获取外文期刊封面封底 >>

       

摘要

To examine treatment patterns, oncological outcomes and toxicity rates in elderly patients receiving radiotherapy for cutaneous squamous cell carcinoma (cSCC) of the head-and-neck region. In this retrospective single-center analysis, locoregional control (LRC), progression-free survival (PFS) and overall survival (OS) of elderly patients??65?years with cSCC of the head-and-neck region undergoing radiotherapy between 2010 and 2019 were calculated. The prognostic value of clinicopathological parameters on radiotherapy outcomes was analyzed using the Cox proportional hazards model. In addition, both acute and chronic toxicities were retrospectively quantified according to CTCAE version 5.0. A total of 69 elderly patients with cSCC of the head-and-neck region with a median age of 85?years were included in this analysis, of whom 21.7% (15 patients) presented with nodal disease. The majority of patients exhibited a good performance status, indicated by a median Karnofsky performance status (KPS) and Charlson Comorbidity Index (CCI) of 80% and 6 points, respectively. Radiotherapy was administered as primary (48%), adjuvant (32%) or palliative therapy (20%). 55 patients (79.7%) completed treatment and received the scheduled radiotherapy dose. Median EQD2 radiation doses were 58.4?Gy, 60?Gy and 51.3?Gy in the definitive, adjuvant and palliative situation, respectively. 2-year LRC, PFS and OS ranged at 54.2%, 33.5 and 40.7%, respectively. Survival differed significantly between age groups with a median OS of 20 vs. 12?months (p??0.05) for patients aged 65–80 or above 80?years. In the multivariate analysis, positive lymph node status remained the only significant prognostic factor deteriorating OS (HR 3.73, CI 1.54–9.03, p??0.01). Interestingly, neither KPS nor CCI impaired survival in this elderly patient cohort. Only 3 patients (4.3%) experienced acute CTCAE grade 3 toxicities, and no chronic CTCAE grade 2–5 toxicities were observed in our cohort. Radiotherapy was feasible and well-tolerated in this distinct population, showing the general feasibility of radiotherapy for cSCC of the head-and-neck region also in the older and oldest olds. The very mild toxicities may allow for moderate dose escalation to improve LRC.
机译:检查老年患者接受头部鳞状细胞癌(CSCC)的老年患者治疗模式,肿瘤学结果和毒性率。在这种回顾性单中心分析中,招诊所控制(LRC),无进展生存(PFS)和老年患者的整体存活率(OS)?&?65?多年与CSCC在接受放射治疗的头颈区域2010年和2019年计算出来。用COX比例危害模型分析了对放射治疗结果的临床病理学参数的预后价值。此外,根据CTCAE 5.0,回顾性地定量急性和慢性毒性。在此分析中,共有69名老年人CSCC患有85岁的头和颈部地区的CSCC患者,其中包括节点疾病的21.7%(15名患者)。大多数患者表现出良好的性能状态,分别表示良好的性能状况,表明了80%和6点的中位Karnofsky性能状态(KPS)和CCI)分别为80%和6分。放射疗法以初级(48%),佐剂(32%)或姑息治疗(20%)施用。 55例患者(79.7%)完成治疗并接受预定放疗剂量。中位数EQD2辐射剂量分别为58.4°,60?GY和51.3?GY分别在最终,佐剂和姑息情况下。 2年LRC,PFS和OS分别为54.2%,33.5和40.7%。年龄组之间的生存率显着差异,中位数为20与12〜12岁或80岁或80岁以上的患者的月份(p?0.05)。在多变量分析中,阳性淋巴结状态仍然是唯一的显着预后因子劣化OS(HR 3.73,CI 1.54-9.03,P≤≤0.01)。有趣的是,这种老年患者队列中的kps和cci障碍都不受损。只有3名患者(4.3%)经历了急性CTCAE级3级毒性,在我们的队列中没有观察到慢性CTCAE级2-5级毒性。在这种明显的人群中,放射疗法是可行和良好的耐受性,显示出在老年人和最旧的老年人的头部和颈部区域的CSCC放射治疗的一般可行性。非常轻微的毒性可能允许适度的剂量升级以改善LRC。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号